Study to Assess the Safety, Tolerability, PK and PD of ABX1100
NCT06109948
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Late Onset Pompe Disease
Interventions
DRUG:
ABX1100 injection for IV infusion
DRUG:
Placebo injection for IV infusion
Sponsor
Aro Biotherapeutics